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ABSTRACT: The aim of this study was to test for a 
potential anticarcinogenic effect of Celergen, a marine 
derivative devoid of traceable amounts of inorganic 
arsenic, on cell proliferation, cell cycle progression 
and apoptosis in the HepG2 human liver cancer cell 
line. Celergen significantly inhibited the proliferation 
of cancer cells in a dose-dependent manner while 
limiting the cell cycle progression at the G1 phase and 
significantly inducing apoptosis. Further examination 
showed that Celergen enhanced expression of the 
p21CIPl1WAF1, GADD153 genes and downregulated the 
c-myc gene. These results suggest that Celergen exerts 
promising chemopreventive properties to be further 
investigated.
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1. Introduction
Marine derivatives, with their immense diversity and 
selection driven along millions of years of evolution may 
offer promising options for new drug discovery (1-5). In 
particular, several marine bioactive compounds are under 
study for their potential antitumor effect (6-9). Although 
the detailed mechanisms involved are still a matter of 
study, antioxidative and antimutagenic properties have 
been advocated for (10-12). We have recently shown that 
Celergen, a popular GMP-controlled marine bioceutical, 
could significantly inhibit ultraviolet (UV)-induced 
matrix-metalloproteinases (MMP) transcription and 
exert an antioxidant effect protecting skin fibroblasts 
(13). On the other hand, most recently the same food 
supplement has been vaguely suggested to be implicated 
in a case report in which the user showed increased 
levels of α-fetoprotein (14). Although this report suffers 
some limitations and a possible major methodological 
flaw, the issue deserved further clarification, given that 
several herbal supplements, once believed as safe or 
even claimed to be "liver protectors" have been recently 
shown to be potentially hepatotoxic or even mutagenic 
(15-18). Thus, the aim of the present study was to test 
the novel biomarine derivative Celergen on in vitro liver 
carcinogenesis.
2. Materials and Methods
2.1. Chemicals
Celergen was obtained from Swisscap company (100 
mg composition: DNA extract from fish milt 46 mg, 
fi sh collagen hydrolysate plus fi sh elastin 35 mg, whole 
fish protein hydrolysate 6 mg, lutein-coenzyme Q10-
selenium 11 mg). As a pre-requisite, samples were 
blindly sent to an offi cial Good Manufacturing Practice 
and Good Laboratory Practice registered toxicology 
laboratory which found no traceable amounts of heavy 
metals including organic and inorganic arsenic, having 
set a threshold of > 5 ppm (Redox Lab, Monza, Italy, 
report n. 2013001054/LAB). 7,12-Dimethylbenz[a]
anthracene (DMBA) and 12-Q-tetradecanoylphorbo-13 
acetate (TPA) were obtained from Sigma-Aldrich 
Corp. (St. Louis, MO, USA). 4-Nitroquinoline I-oxide 
(4NQO) was obtained from Nacalai Tesque Co. (Kyoto, 
Japan). 
2.2. In vitro analysis of cell growth
Human liver cancer cell line HepG2 were cultured in 
DMEM supplemented with 10% fetal bovine serum and 
incubated at 37°C in a humidified atmosphere of 5% 
CO2 in air. HepG2 cells were then seeded at a density 
of  4 × 104 cells/2 mL medium in 35-mm diameter 
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dishes. Celergen were dissolved in tetrahydrofuran 
(THF) including 0.025% butylhydroxytoluene (BHT, 
as an antioxidant) and diluted to its final concentration 
expressed as μg/mL in each culture dish. An equivalent 
volume of vehicle (THF + BHT) was added to control 
dishes and it showed no measurable effect on HepG2 
cells. Celergen was added at graded concentrations 1 day 
following the inoculation. At the 72 h observation, the 
number of viable cells was counted using a trypan blue 
dye exclusion methodology.
2.3. Flow cytometry
Cells were plated at a density of  1 × 106 cells/10 mL 
medium in 100 mm diameter dishes. Celergen was added 
1 day after the inoculation. Cells were harvested from 
culture dishes by trypsinization and centrifugation. After 
a wash with phosphate buffered solution (PBS) (-), cells 
were suspended in a 0.1% Triton X-l00 solution. After 
the suspension was filtered through 50 μm nylon mesh, 
0.1% RNase A and 50 pg/mL propidium iodide were 
added to stain DNA. The DNA content in stained nuclei 
was analyzed by a flow cytometer (FACS Calibur™, 
Becton-Dickinson, Franklin Lakes, NJ, USA). The 
percentage distribution of cells in each cell cycle phase 
was determined using ModFit LT™ software (Becton-
Dickinson) based on DNA histograms. Five separate 
experiments were used each time to determine the final 
values.
2.4. Isolation of total RNA
HepG2 cells were plated at a density of 1 × 106 cells/10 
mL medium in 100 mm diameter dishes. Celergen 
was added 24 h after the inoculation. Total RNA was 
isolated from the cells at pre-fi xed times in the absence 
or presence of Celergen using RNeasyR Kit (QIAGEN 
GmbH, Hilden, Germany). Briefly, total RNA was 
adsorbed onto a silica membrane following cell lysis. 
Membranes were subsequently washed and RNA was 
eluted with 50/11 of RNase-free water. Final RNA 
concentrations were assessed by spectrophotometry.
2.5. Real-time quantitative RT-PCR
Total RNA was isolated from HepG2 cells as described 
above. Total RNA (5 pg) was transcribed to cDNA in 
a 20 μL reaction volume, with Superscript II Reverse 
transcriptase (Invitrogen Corp., Carlsbad, CA, USA), 
using oligo (dT) 12-18 primers. The reaction mixture 
was incubated at 42°C for 50 min, then at 70°C for 
15 min. An equivalent volume of cDNA solution was 
used for the quantification of specific cDNA by real-
time quantitative RT-PCR. The primer sequences 
used were as follows: for the p2lCIPlIWAFl gene (318 
bp), 5'-ATTAGCAGCGGAACAAGGAGTCAGA
CAT3' and 5'-CTGTGAAAGACACAGAACAGT
ACAGGGT-3', for GADD153 (309 bp), 5'GAAA
CGGAAACAGAGTGGTCATTCCCC-3' and 5'- 
GTGGGATTGAGGGTCACATCATTGGCA-3', for 
c-myc (209 bp), 5'-GGCAAAAGGTCAGAGTCTGG-3' 
a n d  5 ' - G T G C AT T T T C G G T T G T T G C - 3 ' ,  f o r 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 
181 bp), 5'-CAACTACATGGTTTACATGTTC-3' 
and 5 ' -GCCAGTGGACTCCACGAC-3' .  Real-
time quantitative RT-PCR was performed with the 
LightCycler™ system (Roche Diagnostics GmbH, 
Mannheim, Germany) using a SYBR Green I Kit as 
instructed by the manufacturer. GAPDH, p2lCIPlIWAFl and 
GADD153 were amplified with a precycling hold at 
95°C for 10min, followed by 30 cycles of denaturation 
at 95°C for 15 s, annealing at 58°C for 5 s, and 
extension at 72°C for 10 s. c-myc was amplified with 
a precycling hold at 95°C for 10 min, followed by 30 
cycles of denaturation at 95°C for 15 s, annealing at 
63°C for 5 s and extension at 72°C for 10 s. To confi rm 
amplification specificity, the PCR products were 
subjected to a melting curve analysis. Quantification 
data were analyzed using LightCycler analysis software. 
The expression levels of p21CIPIIWAF1, GADD153, and 
c-myc were normalized to the level of GAPDH mRNA 
of the same sample.
2.6. Statistical analysis
For statistical analysis "One Way" variance analysis was 
employed and significance between the experimental 
and control groups was determined by Bonferroni's 
method. A difference of p < 0.05 was considered 
signifi cant. Results were expressed as mean ± S.D. 
3. Results
3.1. HepG2 cell proliferation: in vitro effects of Celergen
Treatment of HepG2 cells with Celergen brought 
about a significant inhibition of human liver cancer 
cell proliferation in a dose-dependent manner. Three 
days after the incubation with 25 μM, 50 μM, 100 μM 
and 200 μM Celergen, HepG2 cell growth decreased 
to 63, 52, 38 and 27% of the control, respectively. The 
concentration of Celergen with 50% growth inhibition 
was calculated as 50 μM (Figure 1).
3.2. Effect of Celergen on G1 arrest and apoptosis in 
HepG2 cells
The DNA content of HepG2 cells was calculated 
by flow cytometry analysis to identify whether the 
growth inhibitory effect of Celergen was determined 
by specific actions on cell cycle-related events. From 
DNA histograms it appeared that Celergen enabled a 
not signifi cant trend increase of the ratio of G1 cells, but 
most signifi cantly it increased pre-G1 apoptotic cells at 
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have been recently shown that it exhibits a strong skin 
fi broblast protecting effect against UV irradiation (13).
 In the present study, Celergen was shown to 
significantly inhibit cell growth via induction of 
G1 arrest of the cell cycle and apoptosis in HepG2 
cells. To explore the action mechanism of cell cycle 
inhibition by Celergen, we assessed the expression 
of cell cycle and apoptosis related genes and found 
that the expression of p21CIP1/WAF1 and GADD153 was 
significantly induced by Celergen. It is known that 
p21CIP1/WAF1 is significantly induced by DNA damage 
and regulates the Gl and G2/M checkpoints (19,20) and 
that the induction of p21CIP1/WAF1 usually follows a 
the 72h observation (p < 0.005, Figure 2). On the other 
hand, the effect of Celergen on the cell cycle on days 1 
and 2 was not signifi cant (not shown)..
3.3. Gene expression of p21CIP1/WAF1, GADD153 and 
c-myc expression: effect of Celergen regulation
The effects of Celergen on the expression of cell cycle 
and apoptosis-related genes were examined using real-
time quantitative RT-PCR. Significant induction of 
p21CIPIIWAFl and GADD153 was clearly observed at 48 h 
following treatment with Celergen and it was maintained 
throughout the observation period (72 h) while a 
signifi cant late downregulation of c-myc occurred as well 
(p < 0.01, Figure 3).
4. Discussion
Celergen is a popular marine derivative containing 
DNA, collagen elastin and protein extracts and we 
Figure 1. Growth inhibitory effect of Celergen on HepG2 
cells. Cells were cultured for 72 h with or without Celergen 
at concentrations ranging from 25 to 200 μM. On day 3, the 
number of viable cells was determined. Data are expressed as 
means ± S.D. of three separate experiments.
Figure 2. Effect of Celergen on cell cycle and apoptosis 
in HepG2 cells. HepG2 cells were treated with Celergen at 
ID 50 or ID 75 for 72 h and stained with propidium iodide to 
assess DNA content. The percentage of cells in each phase of 
the cell cycle was assessed by fl ow cytometric analysis. Data 
are expressed as means ± S.D. of fi ve separate experiments. 
Left vertical line indicates the ratio of each phase in viable 
cells. Right vertical line indicates the percentage of apoptotic 
cells. White bars: Gl; dotted bars; S; black bars: G2/M and 
grey bars: apoptosis. * p < 0.01 compared with control.
Figure 3. Effect of Celergen on p21CIP1/WAF1, GADD153, 
and c-myc mRNA expression. Real-time quantitative RT-
PCR was performed with 5 μg of total RNA from HepG2 
cells treated with 50 μM Celergen or vehicle alone (control) 
for the test periods indicated. Values are means ± S.D. of fi ve 
separate tests. All values were normalized to the GAPDH 
expression level. * p < 0.05 compared with control.
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p53 dependent mechanism (21). Moreover, GADD153 
and c-myc are known to be involved in apoptosis 
progression. GADD153 is a member of the CCAAT/
enhancer-binding protein family of transcription factors 
and its expression is markedly enhanced by various 
cellular stresses (22,23). On the other hand, c-myc is a 
proto-oncogene and is implicated in various processes 
including cell growth, proliferation and cell death (24). 
In particular, the overexpression of c-myc represents a 
genetic abnormality frequently found in hepatocellular 
carcinoma (HCC) (25). Indeed, the relevance of 
c-myc expression in HCC has been confirmed in 
transgenic mice studies (26) and in clinics where 
overexpression of this gene is detected in most HCC 
patients while correlating also with poor prognosis 
(27). In our study, the induction of p21CIP1/WAF1 
and GADD153 occurred significantly at 48 h after 
treatment with Celergen and subsequently, an increase 
in G1 phase and apoptotic pre-G1 cells was observed 
at 72 h. However, c-myc showed a late but signifi cant 
downregulation. Since p53 is known to be functional 
in HepG2 cells, p21CIP1/WAF1 is likely to have been 
induced by a mechanism which depends on p53 and 
may be implicated in G1 arrest exerted by Celergen. 
Nonetheless, the induction of apoptosis by Celergen 
may be caused by GADD153 and has to be considered 
as well.
 In summary, our data suggest that Celergen inhibits 
the proliferation of HepG2 cells and induces G1 
arrest and apoptosis. The induction was associated 
with enhanced expression of p21CIP1/WAF1, GADD153 
but suppression of c-myc. These results suggest that 
such marine compounds may have anticarcinogenic 
properties while more fi nely-detailed proteomic studies 
are awaited. This data is in contrast with the albeit 
isolated clinical report of Chua et al. (14) suggesting 
an arsenic-related hepatocarcinogenesis effect of the 
same compound. However, that study bears the main 
methodological bias in that the authors measured the 
whole arsenic content, while the literature has clearly 
demonstrated that only the inorganic component is 
the one with the noxious effect (28) and the only one 
deserving monitoring from major epidemiological 
studies (29,30). On the contrary, the organic one is 
regarded as safe (31) and its concentration may also 
vary (32) as probably occurred in their study. For 
instance, seafood and seaweeds generally contain 
almost completely nontoxic organic arsenic such 
as arsenosugars (33). Thus, their suggestion cannot 
be supported and their observed abnormality of 
α-fetoprotein observed in their case report has to be 
correlated to other factors (episodic afl atoxin exposure, 
either environmental or food-borne etc.) which have not 
been analyzed in their report together with the lack of a 
separate measurement of organic and inorganic arsenic 
content. From the above, the study of Chua et al. has 
to be disregarded similarly because of what happened 
199
with a similar case of a different seafood compound 
after review by a number of experts in the field (34-
36). While our study needs further research and in 
vivo follow up, our general conclusion is that marine 
derivatives, if properly farmed, collected and processed 
maintain a promising potential as a safe source of 
benefi cial treatment.
References
1. Lorenzetti A, Marotta F, Yadav H, Celep G, Minelli 
E, Carrera-Bastos P, Jain S, Polimeni A, Solimene U. 
Improving sperm quality and spermatogenesis through 
a bioactive marine compound: An experimental study. 
Acta Biomed. 2012; 83:108-113.
2. Catanzaro R, Marotta F, Jain S, Rastmanesh R, Allegri F, 
Celep G, Lorenzetti A, Polimeni A, Yadav H. Beneficial 
effect of a sturgeon-based bioactive compound on 
gene expression of tumor necrosis factor-alpha, matrix 
metalloproteinases and type-10 collagen in human 
chondrocytes. J Biol Regul Homeost Agents. 2012; 
26:337-345.
3. Newman DJ, Cragg GM. Marine natural products and 
related compounds in clinical and advanced preclinical 
trials. J Nat Prod. 2004; 67:1216-1238.
4. Cabrita MT, Vale C, Rauter AP. Halogenated compounds 
from marine algae. Mar Drugs. 2010; 8:2301-2317.
5. Newman DJ, Cragg GM. Advanced preclinical and 
clinical trials of natural products and related compounds 
from marine sources. Curr Med Chem. 2004; 11:1693-
1713.
6. Simmons TL, Andrianasolo E, McPhail K, Flatt P, 
Gerwick WH. Marine natural products as anticancer 
drugs. Mol Cancer Ther. 2005; 4:333-342.
7. Singh R, Sharma M, Joshi P, Rawat DS. Clinical status 
of anti-cancer agents derived from marine sources. 
Anticancer Agents Med Chem. 2008; 8:603-617.
8. Provencio M, Sánchez A, Gasent J, Gómez P, Rosell R. 
Cancer treatments: Can we find treasures at the bottom 
of the sea? Clin Lung Cancer. 2009; 10:295-300.
9. Jimeno J, López-Martín JA, Ruiz-Casado A, Izquierdo 
MA, Scheuer PJ, Rinehart K. Progress in the clinical 
development of new marine-derived anticancer 
compounds. Anticancer Drugs. 2004; 15:321-329.
10. Tang HG, Wu TX, Zhao ZY, Pan XD. Effects of fish 
protein hydrolysate on growth performance and humoral 
immune response in large yellow croaker (Pseudosciaena 
crocea R.). J Zhejiang Univ Sci B. 2008; 9:684-690.
11. T h e o d o r e A E , R a g h a v a n S , K r i s t i n s s o n H G . 
Antioxidative activity of protein hydrolysates prepared 
from alkaline-aided channel catfish protein isolates. J 
Agric Food Chem. 2008; 56:7459-7466.
12. Yang Y, Zhang Z, Pe, X, Han H, Wang J, Wang L, 
Long Z, Shen X, Li Y. Immunomodulatory effects of 
marine oligopeptide preparation from Chum Salmon 
(Oncorhynchus keta) in mice. Food Chem. 2009; 
113:464-470.
13. Marotta F, Kumari A, Yadav H, Polimeni A, Soresi 
V, Lorenzetti A, Naito Y, Jain S. Biomarine extracts 
significantly protect from ultraviolet A-induced skin 
photoaging: An ex vivo study. Rejuvenation Res. 2012; 
15:157-160.
14. Chua C , Tan IB , Choo SP, Toh HC. Inc reased 
www.ddtjournal.com
Drug Discoveries & Therapeutics. 2013; 7(5):196-200. 200
α-fetoprotein likely induced by complementary health 
products. J Clin Oncol. 2013; 31:e80-82. 
15. Navarro VJ, Bonkovsky HL, Hwang SI, Vega M, 
Barnhart H, Serrano J. Catechins in dietary supplements 
and hepatotoxicity. Dig Dis Sci. 2013; 58:2682-2690.
16. Teschke R, Schwarzenboeck A, Eickhoff A, Frenzel C, 
Wolff A, Schulze J. Clinical and causality assessment 
in herbal hepatotoxicity. Expert Opin Drug Saf. 2013; 
12:339-366.
17. Brandon-Warner E, Eheim AL, Foureau DM, Walling 
TL, Schrum LW, McKillop IH. Silibinin (Milk Thistle) 
potentiates ethanol-dependent hepatocellular carcinoma 
progression in male mice. Cancer Lett. 2012; 326:88-95.
18. McCormick DL, Hollister JL, Bagg BJ, Long RE. 
Enhancement of murine hepatocarcinogenesis by all-
trans-retinoic acid and two synthetic retinamides. 
Carcinogenesis. 1990; 11:1605-1609.
19. Dang CV. c-Myc target genes involved in cell growth, 
apoptosis, and metabolism. Mol Cell Biol. 1999; 19:1-11.
20. Kurland JF, Tansey WP. Myc-mediated transcriptional 
repression by recruitment of histone deacetylase. Cancer 
Res. 2008; 68:3624-3629.
21. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus 
RC, Li F. The c-Myc target gene network. Semin Cancer 
Biol. 2006; 16:253-264.
22. Liao Y, Fung TS, Huang M, Fang SG, Zhong Y, Liu DX. 
Up-regulation of CHOP/GADD153 during coronavirus 
infectious bronchitis virus infection modulates apoptosis 
by restricting activation of the extracellular signal-
regulated kinase pathway. J Virol. 2013; 87:8124-8134.
23. De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez 
ES, De Siervi A. BRCA1 and p53 regulate critical 
prostate cancer pathways. Prostate Cancer Prostatic Dis. 
2013; 16:233-238.
24. Zhao Y, Jian W, Gao W, Zheng YX, Wang YK, Zhou 
ZQ, Zhang H, Wang CJ. RNAi silencing of c-Myc 
inhibits cell migration, invasion, and proliferation in 
HepG2 human hepatocellular carcinoma cell line: c-Myc 
silencing in hepatocellular carcinoma cell. Cancer Cell 
Int. 2013; 13:23-28. 
25. Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting 
c-Myc as a novel approach for hepatocellular carcinoma. 
World J Hepatol. 2010; 2:16-20
26. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko 
A, Arzeno J, Yang Q, Gambhir SS, Felsher DW. MYC 
phosphorylation, activation, and tumorigenic potential 
in hepatocellular carcinoma are regulated by HMG-CoA 
reductase. Cancer Res. 2011; 71:2286-2297.
27. Peng S, Lai P, Hsu H. Amplification of the c-myc gene in 
human hepatocellular carcinoma: biologic significance. J 
Formos Med Assoc. 1993; 92:866. 
28. Huang CY, Su CT, Chung CJ, Pu YS, Chu JS, Yang 
HY, Wu CC, Hsueh YM. Urinary total arsenic and 
8-hydroxydeoxyguanosine are associated with renal cell 
carcinoma in an area without obvious arsenic exposure. 
Toxicol Appl Pharmacol. 2012; 262:349-354.
29. Calderon RL, Hudgens EE, Carty C, He B, Le XC, 
Rogers J, Thomas DJ. Biological and behavioral factors 
modify biomarkers of arsenic exposure in a U.S. 
population. Environ Res. 2013; 126:134-144.
30. Osorio-Yáñez C, Ayllon-Vergara JC, Aguilar-Madrid G, 
Arreola-Mendoza L, Hernández-Castellanos E, Barrera-
Hernández A, De Vizcaya-Ruiz A, Del Razo LM. 
Carotid intima-media thickness and plasma asymmetric 
dimethylarginine in mexican children exposed to 
inorganic arsenic. Environ Health Perspect. 2013; 
121:1090-1096.
31. Francesconi KA, Edmonds JS. Arsenic and marine 
organisms. In: Advances in Inorganic Chemistry, Vol. 44. 
1997; 44:147.
32. Taylor VF, Jackson BP, Siegfried M, Navratilova 
J, Francesconi KA, Kirshtein J, Voytek M. Arsenic 
s p e c i a t i o n i n f o o d c h a i n s f r o m m i d - A t l a n t i c 
hydrothermal vents. Environ Chem. 2012; 9:130-138.
33. Kaise TOY, Ochi T, Okubo T, Hanaoka K, Irgolic KJ, 
Sakurai T, Matsubara C. Toxicological study of organic 
arsenic compound in marine algae using mammalian cell 
culture technique. J Food Hyg Soc Jpn. 1996; 37:135-141.
34. Fabricant D. Arsenic in herbal kelp supplements: 
concentration, regulations, and labeling. Environ Health 
Perspect. 2007; 115:A574.
35. Lewis AS. Organic versus inorganic arsenic in herbal 
kelp supplements. Environ Health Perspect. 2007; 
115:A575.
36. McGuffin M, Dentali S. Safe use of herbal kelp 
supplements. Environ Health Perspect. 2007; 115:A575-
576.
 (Received September 6, 2013; Revised October 10, 2013, 
Re-revised October 26, 2013; Accepted October 28, 2013)
